GlassScriptPhysician profile
Laura E Hudson
NPI 1659723286
$14,082.33
in general payments reported to CMS, 2019-2025
28 companies · $2,109 in 2025
The $2,109 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $981 · 2022: $1,041 · 2023: $3,532 · 2024: $6,419 · 2025: $2,109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Education: $126.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,533.66 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Education | $125.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lumenis Be INC | $7,159.41 | 2023-2025 | Optilight, M22 |
| Abbvie INC. | $2,304.26 | 2021-2025 | |
| Pfizer INC. | $659.17 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $553.08 | 2021-2025 | Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $474.58 | 2022-2025 | |
| Astellas Pharma US INC | $440.63 | 2021-2025 | Veozah, Myrbetriq |
| Senseonics, Incorporated | $400.00 | 2025 | Eversense |
| Takeda Pharmaceuticals U.S.A., INC. | $286.30 | 2022-2025 | Cuvitru, Trintellix |
| Lundbeck LLC | $274.34 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $246.07 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Biohaven Pharmaceutical Holding Company LTD. | $227.04 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $197.45 | 2021-2023 | Trulance, Xifaxan |
| Teva Pharmaceuticals USA, INC. | $124.04 | 2024-2025 | Austedo Xr, Austedo Xr |
| Janssen Pharmaceuticals, INC | $103.83 | 2023 | Spravato |
| Allergan, INC. | $83.17 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $75.36 | 2021-2022 | |
| Ibsa Pharma INC. | $69.71 | 2024-2025 | Licart, Flector, Tirosint |
| Biohaven Pharmaceuticals, INC. | $68.88 | 2021 | |
| Exact Sciences Corporation | $60.42 | 2025 | The Cologuard Plus Collection Kit |
| Lilly USA, LLC | $58.26 | 2025 | Zepbound, Mounjaro |
| Paratek Pharmaceuticals, INC. | $54.64 | 2024-2025 | Nuzyra, Xhance |
| Mayne Pharma Commercial LLC | $27.00 | 2021 | |
| Seqirus USA INC | $26.81 | 2025 | Fluad, Flucelvax |
| Organon LLC | $24.88 | 2022 | |
| Acella Pharmaceuticals, LLC | $21.66 | 2023 | NP Thyroid 60 |
| Daiichi Sankyo INC. | $21.61 | 2023 | Injectafer |
| Azurity Pharmaceuticals, INC. | $20.27 | 2023 | Adthyza |
| Abbott Laboratories | $19.46 | 2023 | Freestyle Libre 3 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.